Probi AB (publ) (PROB.ST)
Probi AB (publ) operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Lund, SE. The stock last traded at $348.00, up 0.00% on the session, giving a market capitalisation of $3.97B. Its beta of 0.46 implies it has historically moved less than the broad market.
Probi AB (publ) specializes in the research, development, manufacturing, marketing, and distribution of probiotics for the health, pharmaceutical, and food sectors. The company's scientific endeavors primarily focus on areas such as gastrointestinal, digestive, immune, and bone health, as well as iron absorption, and the specific health requirements of children, women, and seniors. Their product range includes dietary supplements and various food and beverage applications, offered in diverse formats like capsules, tablets (including chewable), spheres, powders, and an array of drinks such as fruit drinks, shots, carbonated beverages, and recovery drinks. Probi's products are sold in approximately 40 countries globally. The company also fosters collaborations, including a partnership with Örebro University for exploring needle-free vaccines and with La Trobe University for a clinical trial assessing the effects of Probi Osteo in Australian women. Established in 1991 and headquartered in Lund, Sweden, Probi AB (publ) operates as a subsidiary of Symrise AG.
Probi AB (publ) is most often compared with the following Healthcare names: